Rekha Hemrajani

Executive

BioAge Labs, Inc.Maxcyte, Inc.ALX Oncology Holdings Inc

Insider activity · 24 months1 buy1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 1 buy · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 1 saleJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€92k

▼ Sales (1 ops.)

€19k

Latest filing published 27 Aug 2025 for Maxcyte, INC., €19k. Read the official filing

Filing timeline

BuySale

Rekha Hemrajani

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

BioAge Labs, Inc. 1 purchase · last 10 Mar 2025
ALX Oncology Holdings INC 1 purchase · last 04 Dec 2024

Since each purchase

BioAge Labs, Inc.
Filed 10 Mar 2025 · 587 days ago · €48k
+356.1%
Entry US$4.40 · Close at T+365 US$20.07

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Rekha Hemrajani: trading record in brief

Rekha Hemrajani discloses dealings in 3 companies, chiefly Maxcyte, Inc., ALX Oncology Holdings Inc and BioAge Labs, Inc. Between 11 June 2024 and 25 June 2025, the trades on record add up to 5 filings.

Both buying and selling appear: 2 purchases worth €92k, against 1 sale worth €19k. Purchases outweigh sales by €73k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 2 share grants. In 2025 alone, the filings show 1 purchase and 1 sale.

On 27 August 2025 came the latest disclosure, an open-market sale for €19k in Maxcyte, Inc. The last purchase on record was published on 10 March 2025, which is 587 days ago. The median gap between a trade and its publication by SEC (Form 4) is 5 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.